JAK2 and myeloproliferative neoplasm: Identification of the JAK2 V617F mutation, now over a decade ago, revolutionised the molecular diagnosis of MPN as this mutation is present in up to 95% of patients with PV and in approximately 50–60% of patients with ET and PMF.